Conference abstractPublished 7 Mar 2016
Enhanced delivery of DNA-based vaccines and immunotherapeutics through next-generation electroporation devices
Inovio Pharmaceuticals Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
It is well known that naked DNA vaccination alone is insufficient to generate clinically relevant immune responses due to inefficient cellular uptake. In vivo electroporation (EP) has been shown as an efficient non-viral method for enhancing DNA vaccine delivery and immunogenicity in animals and humans over the past twenty years. In a recent randomized, double-blind, placebo-controlled phase 2b study, Inovio Pharmaceuticals has successfully demonstrated therapeutic vaccination of CIN2/3 patients with VGX-3100, a highly optimized HPV-16/18 DNA vaccine, administered by CELLECTRA® EP device resulted in robust cellular and humoral immune responses, significant viral clearance and, importantly, significant regression to CIN1 or no disease. Inovio is currently developing additional EP devices for DNA delivery to a variety of tissues, such as muscle and skin. One of the examples- Surface Electroporation Device (SEP), which only contacts the surface of the skin and does not penetrate the skin, is capable of efficient delivery of DNA vaccines into the skin while establishing that these parameters are sufficient to elicit both robust and sustainable humoral as well as cellular immune responses without tissue damage. Here we will discuss the impact of these devices on in vivo DNA uptake and how different EP strategies can be used to optimize delivery of DNA-based vaccines and immunotherapeutics for a variety of therapeutic indications for different applications.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGenetics & Molecular Biology
- SubjectImmunology & Microbiology
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Paul Fisher”